keyword
MENU ▼
Read by QxMD icon Read
search

Non Clear Cell RCC

keyword
https://www.readbyqxmd.com/read/28913767/management-of-atypical-renal-cell-carcinomas
#1
REVIEW
Bobby C Liaw, Reza Mehrazin, Charles Baker, John P Sfakianos, Che-Kai Tsao
Non-clear cell renal cell carcinoma (RCC) encompasses a diverse group of diseases, with research yielding different histologic findings and genetic profiles with each distinct subgroup. Simply mirroring the management techniques of clear cell RCC and borrowing from its growing armamentarium of therapeutic agents, while somewhat productive at first, but will ultimately be limiting. Further investigation into the molecular pathogenesis of disease, similarities and differences between specific subtypes, and mechanisms of resistance to therapeutics will help identify new targets, stimulate development of novel agents, and improve clinical trial offerings for non-clear cell RCC (nccRCC)...
September 14, 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28816276/-percutaneous-biopsy-of-the-renal-masses-under-ultrasound-a-single-center-14-years-experience
#2
Y X Zhang, X B Meng, L Yao, C J Zhang, G Song, L Cai, Z Zhang, X S Li, K Gong, S Q Li, G Z Shan, Q He, X Y Yang, Z S He, L Q Zhou
OBJECTIVE: To assess the diagnostic rate, safety and clinical application of percutaneous renal masses biopsy for advanced renal cell carcinoma patients. METHODS: In this retrospective study, we collected the data of renal masses from the patients who underwent renal masses biopsy under ultrasound from April 2001 to December 2014 in Peking University First Hospital. A total of 75 patients who were undiagnosed or diagnosed with advanced renal cell carcinoma by the imageological method were enrolled in this study...
August 18, 2017: Beijing da Xue Xue Bao. Yi Xue Ban, Journal of Peking University. Health Sciences
https://www.readbyqxmd.com/read/28811845/role-of-contrast-enhancement-and-corrected-attenuation-values-of-renal-tumors-in-predicting-renal-cell-carcinoma-rcc-subtypes-protocol-for-a-triphasic-multi-slice-computed-tomography-ct-procedure
#3
Ersen Ertekin, Akın Soner Amasyalı, Bulent Erol, Saim Acikgozoglu, Faruk Kucukdurmaz, Alaaddin Nayman, Haluk Erol
BACKGROUND: To distinguish RCC subtypes based on contrast enhancement features of CT images. MATERIAL/METHODS: In total, 59 lesions from 57 patients were included. All patients underwent multi-slice CT imaging with a triphasic protocol, which included non-contrast, corticomedullary, nephrographic and urographic phases. Contrast enhancement features of renal masses were evaluated in terms of CT attenuation values (AV) and differences in contrast density; the aorta or renal parenchyma were evaluated based on corrected or relative values...
2017: Polish Journal of Radiology
https://www.readbyqxmd.com/read/28793269/cell-type-specific-gene-programs-of-the-normal-human-nephron-define-kidney-cancer-subtypes
#4
David Lindgren, Pontus Eriksson, Krzysztof Krawczyk, Helén Nilsson, Jennifer Hansson, Srinivas Veerla, Jonas Sjölund, Mattias Höglund, Martin E Johansson, Håkan Axelson
Comprehensive transcriptome studies of cancers often rely on corresponding normal tissue samples to serve as a transcriptional reference. In this study, we performed in-depth analyses of normal kidney tissue transcriptomes from the TCGA and demonstrate that the histological variability in cellularity, inherent in the kidney architecture, lead to considerable transcriptional differences between samples. This should be considered when comparing expression profiles of normal and cancerous kidney tissues. We exploited these differences to define renal-cell-specific gene signatures and used these as a framework to analyze renal cell carcinoma (RCC) ontogeny...
August 8, 2017: Cell Reports
https://www.readbyqxmd.com/read/28743221/components-of-metabolic-syndrome-and-prognosis-of-renal-cell-cancer
#5
Tommi J Eskelinen, Andres Kotsar, Teuvo L J Tammela, Teemu J Murtola
OBJECTIVE: This study analyzes risk associations between metabolic syndrome (MetS) components and the extent and prognosis of renal cell cancer (RCC). The independent effect of each MetS component is unclear, but they may affect RCC prognosis. MATERIALS AND METHODS: The study included 13,873 RCC patients (7720 men, 6153 women) diagnosed in Finland in 1995-2012. Data on MetS components (hypertension, dyslipidemia, diabetes and obesity) were obtained as recorded diagnoses or drug purchases related to these conditions...
July 26, 2017: Scandinavian Journal of Urology
https://www.readbyqxmd.com/read/28742884/reduced-expression-of-e-cadherin-and-increased-sialylation-level-in-clear-cell-renal-cell-carcinoma
#6
Małgorzata Borzym-Kluczyk, Iwona Radziejewska, Marzanna Cechowska-Pasko, Barbara Darewicz
Cancer cells are characterized by an aberrant increase in protein N-glycosylation and by disruption of E-cadherin-mediated adherens junctions. However, the relationship between alterations in N-glycosylation process and loss of E-cadherin adhesion in cancer remains unclear. The mechanisms of altered expression of adhesive glycoproteins in cancer cells have not been fully elucidated. Thus, the aim of this study was to examine the expression of E-cadherin and sialyl Lewis(a)/(x), NeuAcα2-3Gal, NeuAcα2-6Gal/GalNAc structures in the normal renal tissue and intermediate and cancerous tissues from patients with clear cell RCC...
2017: Acta Biochimica Polonica
https://www.readbyqxmd.com/read/28731496/prognostic-factors-for-survival-in-metastatic-renal-cell-carcinoma-patients-with-brain-metastases-receiving-targeted-therapy
#7
Ibrahim Yildiz, Ahmet Bilici, Nuri Karadurmuş, Leyla Ozer, Deniz Tural, Mehmet A Kaplan, Tülay Akman, Ibrahim V Bayoglu, Mükremin Uysal, Yaşar Yildiz, Özgür Tanriverdi, Ozan Yazici, Zeki Sürmeli, Nazim Serdar Turhal, Sevil Bavbek, Fatih Selçukbiricik, Doğan Koca, Mert Basaran
BACKGROUND: The primary objective of our study was to examine the clinical outcomes and prognosis of patients with metastatic renal cell carcinoma (mRCC) with brain metastases (BMs) receiving targeted therapy. PATIENTS AND METHODS: Fifty-eight patients from 16 oncology centers for whom complete clinical data were available were retrospectively reviewed. RESULTS: The median age was 57 years (range 30-80). Most patients underwent a nephrectomy (n = 41; 70...
July 14, 2017: Tumori
https://www.readbyqxmd.com/read/28728992/retroperitoneal-lymphadenectomy-in-high-risk-non-metastatic-renal-cell-carcinoma-an-analysis-of-the-assure-ecog-acrin-2805-adjuvant-trial
#8
Benjamin T Ristau, Judi Manola, Naomi B Haas, Daniel Y C Heng, Edward M Messing, Christopher G Wood, Christopher J Kane, Robert S DiPaola, Robert G Uzzo
PURPOSE: Lymphadenectomy (LND) is a well-established practice in many urologic malignancies; however, its role in renal cell carcinoma (RCC) is less clear. Our primary objective was to determine whether LND impacted survival in patients with fully resected high-risk RCC. PATIENTS AND METHODS: Patients with fully resected high-risk, non-metastatic RCC were randomized to adjuvant sorafenib, sunitinib, or placebo in the Adjuvant Sorafenib and Sunitinib for Unfavorable Renal Carcinoma (ASSURE) trial...
July 17, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28710314/sarcomatoid-renal-cell-carcinoma-has-a-distinct-molecular-pathogenesis-driver-mutation-profile-and-transcriptional-landscape
#9
Zixing Wang, Tae Beom Kim, Bo Peng, Jose A Karam, Chad J Creighton, Aron Y Joon, Fumi Kawakami, Patricia Trevisan, Eric Jonasch, Chi-Wan Chow, Jaime Rodriguez-Canales, Pheroze Tamboli, Nizar M Tannir, Christopher G Wood, Federico A Monzon, Keith A Baggerly, Marileila Varella-Garcia, Bogdan Czerniak, Ignacio I Wistuba, Gordon B Mills, Kenna Shaw, Ken Chen, Kanishka Sircar
Sarcomatoid renal cell carcinoma (SRCC) ranks among the most aggressive clinicopathologic phenotypes of RCC. However, the paucity of high-quality, genome-wide molecular examinations of SRCC has hindered our understanding of this entity.<br /><br />Experimental Design: We interrogated the mutational, copy number, and transcriptional characteristics of SRCC and compared these data with those of non-sarcomatoid RCC (RCC). We evaluated whole exome sequencing, single nucleotide polymorphism, and RNA sequencing data from patients with SRCC (n=65) and RCC (n=598) across different parent RCC subtypes, including clear cell RCC, papillary RCC, and chromophobe RCC subtypes...
July 14, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28705707/gata3-as-a-valuable-marker-to-distinguish-clear-cell-papillary-renal-cell-carcinomas-from-morphologic-mimics
#10
Jose G Mantilla, Tatjana Antic, Maria Tretiakova
Clear cell papillary renal cell carcinoma (CCPRCC) is a low-grade, indolent neoplasm, with no reported cases of death from disease or metastasis. These lesions can show clinical, morphologic and immunophenotypic overlap with several aggressive forms of renal cell carcinoma (RCC), including clear cell (CCRCC), translocation RCC and papillary RCC (PRCC) with cytoplasmic clearing. Given the difference in behavior, it is important to reliably separate these entities. We retrospectively reviewed 47 tumors from 45 patients with morphologic features of CCPRCC...
July 10, 2017: Human Pathology
https://www.readbyqxmd.com/read/28694731/detection-of-let-7-mirnas-in-urine-supernatant-as-potential-diagnostic-approach-in-non-metastatic-clear-cell-renal-cell-carcinoma
#11
Michal Fedorko, Jaroslav Juracek, Michal Stanik, Marek Svoboda, Alexandr Poprach, Tomas Buchler, Dalibor Pacik, Jan Dolezel, Ondrej Slaby
INTRODUCTION: Urinary microRNAs (miRNAs) are emerging as a clinically useful tool for early and non-invasive detection of various types of cancer. The aim of this study was to evaluate whether let-7 family miRNAs differ in their urinary concentrations between renal cell carcinoma (RCC) cases and healthy controls. MATERIALS AND METHODS: In the case-control study, 69 non-metastatic clear-cell RCC patients and 36 gender/age-matched healthy controls were prospectively enrolled...
June 15, 2017: Biochemia Medica: časopis Hrvatskoga Društva Medicinskih Biokemičara
https://www.readbyqxmd.com/read/28654897/secreted-mir-210-3p-as-non-invasive-biomarker-in-clear-cell-renal-cell-carcinoma
#12
Vincenzo Petrozza, Antonio Luigi Pastore, Giovanni Palleschi, Claudia Tito, Natale Porta, Serena Ricci, Chiara Marigliano, Manuela Costantini, Giuseppe Simone, Angelina Di Carlo, Michele Gallucci, Antonio Carbone, Francesco Fazi
The most common subtype of renal cell carcinoma (RCC) is clear cell RCC (ccRCC). It accounts for 70-80% of all renal malignancies representing the third most common urological cancer after prostate and bladder cancer. The identification of non-invasive biomarkers for the diagnosis and responsiveness to therapy of ccRCC may represent a relevant step-forward in ccRCC management. The aim of this study is to evaluate whether specific miRNAs deregulated in ccRCC tissues present altered levels also in urine specimens...
June 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/28647866/coffee-consumption-and-risk-of-renal-cell-carcinoma
#13
Samuel O Antwi, Jeanette E Eckel-Passow, Nancy D Diehl, Daniel J Serie, Kaitlynn M Custer, Michelle L Arnold, Kevin J Wu, John C Cheville, David D Thiel, Bradley C Leibovich, Alexander S Parker
BACKGROUND: Studies have suggested an inverse association between coffee consumption and risk of renal cell carcinoma (RCC); however, data regarding decaffeinated coffee are limited. METHODS: We conducted a case-control study of 669 incident RCC cases and 1,001 frequency-matched controls. Participants completed identical risk factor questionnaires that solicited information about usual coffee consumption habits. The study participants were categorized as non-coffee, caffeinated coffee, decaffeinated coffee, or both caffeinated and decaffeinated coffee drinkers...
August 2017: Cancer Causes & Control: CCC
https://www.readbyqxmd.com/read/28639257/large-scale-genome-wide-screening-of-circulating-micrornas-in-clear-cell-renal-cell-carcinoma-reveals-specific-signatures-in-late-stage-disease
#14
Estelle Chanudet, Magdalena B Wozniak, Liacine Bouaoun, Graham Byrnes, Anush Mukeriya, David Zaridze, Paul Brennan, David C Muller, Ghislaine Scelo
Circulating miRNAs have shown great promises as noninvasive diagnostic and predictive biomarkers in several solid tumors. While the miRNA profiles of renal tumors have been extensively explored, knowledge of their circulating counterparts is limited. Our study aimed to provide a large-scale genome-wide profiling of plasma circulating miRNA in clear-cell renal cell carcinoma (ccRCC). Plasma samples from 94 ccRCC cases and 100 controls were screened for 754 circulating micro-RNAs (miRNA) by TaqMan arrays. Analyses including known risk factors for renal cancer-namely, age, sex, hypertension, obesity, diabetes, tobacco smoking and alcohol consumption-highlighted that circulating miRNA profiles were tightly correlated with the stage of the disease...
June 22, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28596583/dynamic-contrast-enhanced-mri-in-renal-tumors-common-subtype-differentiation-using-pharmacokinetics
#15
Hai-Yi Wang, Zi-Hua Su, Xiao Xu, Ning Huang, Zhi-Peng Sun, Ying-Wei Wang, Lu Li, Ai-Tao Guo, Xin Chen, Xin Ma, Lin Ma, Hui-Yi Ye
Preoperative renal tumor subtype differentiation is important for radiology and urology in clinical practice. Pharmacokinetic data (K (trans) & V e, etc.) derived from dynamic contrast-enhanced MRI (DCE-MRI) have been used to investigate tumor vessel permeability. In this prospective study on DCE-MRI pharmacokinetic studies, we enrolled patients with five common renal tumor subtypes: clear cell renal cell carcinoma (ccRCC; n = 65), papillary renal cell carcinoma (pRCC; n = 12), chromophobic renal cell carcinoma (cRCC; n = 9), uroepithelial carcinoma (UEC; n = 14), and fat-poor angiomyolipoma (fpAML; n = 10)...
June 8, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28592625/current-clinical-practice-guidelines-for-the-treatment-of-renal-cell-carcinoma-a-systematic-review-and-critical-evaluation
#16
Aristotle Bamias, Bernard Escudier, Cora N Sternberg, Flora Zagouri, Athanasios Dellis, Bob Djavan, Kimon Tzannis, Loukas Kontovinis, Konstantinos Stravodimos, Athanasios Papatsoris, Dionysios Mitropoulos, Charalampos Deliveliotis, Meletios-Athanasios Dimopoulos, Constantine A Constantinides
The landscape of local and systemic therapy of renal cell carcinoma (RCC) is rapidly changing. The increase in the incidental finding of small renal tumors has increased the application of nephron-sparing procedures, while ten novel agents targeting the vascular endothelial growth factor (VEGF) or the mammalian target of rapamycin pathways, or inhibiting the interaction of the programmed death 1 receptor with its ligand, have been approved since 2006 and have dramatically improved the prognosis of metastatic RCC (mRCC)...
June 2017: Oncologist
https://www.readbyqxmd.com/read/28591094/non-clear-cell-renal-cell-carcinomas-biological-insights-and-therapeutic-challenges-and-opportunities
#17
Gabriel G Malouf, Richard W Joseph, Amishi Y Shah, Nizar M Tannir
The non-clear cell renal cell carcinomas (nccRCCs) are a diverse group of rare-variant renal carcinomas. Each subtype harbors a distinct cell of origin and exhibits a distinct clinical behavior and response to therapy. The advent of next-generation sequencing has drastically advanced our understanding of key genetic and epigenetic drivers in these tumors, although mechanistic studies are needed to elucidate pathogenesis. The only 2 randomized clinical trials in nccRCC included patients with diverse histologic subtypes...
May 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28561708/systemic-therapy-for-non-clear-cell-renal-cell-carcinoma
#18
Tian Zhang, Jun Gong, Manuel Caitano Maia, Sumanta K Pal
Treatment options for metastatic clear cell renal cell carcinoma (ccRCC) have evolved markedly over the past decade, with multiple targeted therapies approved for the disease. In contrast, little improvement has been made in the management of metastatic non-clear cell RCC (nccRCC). Non-clear cell disease is an umbrella term that encompasses multiple biologically distinct entities, including but not limited to papillary, chromophobe, and sarcomatoid RCC. To date, prospective studies have largely explored treatments for ccRCC (e...
2017: American Society of Clinical Oncology Educational Book
https://www.readbyqxmd.com/read/28558989/preoperative-cholesterol-level-is-associated-with-worse-pathological-outcomes-and-postoperative-survival-in-localized-renal-cell-carcinoma-patients-a-propensity-score-matched-study
#19
Hakmin Lee, Chang Wook Jeong, Cheol Kwak, Hyeon Hoe Kim, Seong Il Seo, Hyun Moo Lee, Jong Jin Oh, Sang Chul Lee, Sung Kyu Hong, Sang Eun Lee, Seok-Soo Byun
INTRODUCTION: Lipid metabolism has been suggested to be associated with clinical outcomes of renal cell carcinoma (RCC). In this study, we aimed to investigate the relationship between preoperative cholesterol level (PCL) and postoperative outcomes of patients with localized RCC. MATERIALS AND METHODS: We retrospectively analyzed the data of 5022 patients surgically treated for nonmetastatic RCC. According to the receiver operating curve of PCL for cancer-specific mortality, we stratified the patients into 2 groups by using a cutoff value of 161 mg/dL...
May 10, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28549248/metastatic-chromophobe-renal-cell-carcinoma-treated-with-targeted-therapies-a-renal-cross-channel-group%C3%A2-study
#20
MULTICENTER STUDY
Emeline Colomba, Gwénaël Le Teuff, Tim Eisen, Grant D Stewart, Kate Fife, James Larkin, Andrea Biondo, Lisa Pickering, Anandagopal Srinivasan, Helen Boyle, Lisa Derosa, Cora N Sternberg, Federica Recine, Christy Ralph, Carolina Saldana, Philippe Barthélémy, Jean Christophe Bernhard, Howard Gurney, Gregory Verhoest, Elodie Vauleon, Pierre Bigot, Julien Berger, Christian Pfister, Gwenaelle Gravis, Jean-Michel Rodier, Stéphane Culine, Armelle Caty, Frederic Rolland, Franck Priou, Bernard Escudier, Laurence Albiges
BACKGROUND: Treatment of non-clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR) inhibitors are used, extrapolating the data from use of these agents in clear cell RCC. METHODS: We performed a retrospective data analysis within the Renal Cross Channel Group to determine metastatic chromophobe RCC (mChRCC) outcomes in the TT era...
July 2017: European Journal of Cancer
keyword
keyword
104989
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"